title: Vascular smooth muscle cell signaling in cirrhosis and portal hypertension.
abstract: Abnormal vascular responsiveness to ligands has been frequently observed in cirrhosis and portal hypertension, but its existence is not proven. The signaling pathways in vascular smooth muscle cells (VSMCs) have been studied only in animal models of cirrhosis and portal hypertension. Emerging evidence suggests that active relaxation, expressed as augmented content or activity of effectors within the cyclic AMP signaling pathway and suppressed content or activity of effectors in the inositol 1,4,5-trisphosphate/1,2-diacylglycerol signaling pathway, may be occurring in VSMCs of the splanchnic circulation in portal hypertension. The evidence supporting the existence of this phenomenon in the VSMCs of extrasplanchnic circulations in portal hypertension, as well as in the splanchnic circulation when chronic cellular damage is present, is very limited. The status of the other signaling pathways associated with contractile functions of the VSMCs, viz., cyclic GMP and tyrosine kinase-linked pathways, is unknown. The status of all the signaling pathways in non-contractile functions of VSMCs, such as growth and remodeling, has not been studied. As our overall understanding on the signaling pathways in VSMCs is only emerging, it is premature to implicate altered activity of the signaling pathways as the underlying basis of vascular hyporesponsiveness in cirrhosis and portal hypertension, and to extrapolate these limited observations to the human condition.
authors.affiliation: Department of Pharmacology, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, P.O. Box 9649, Haifa 31096, Israel. bomzon@tx.technion.ac.il
authors.forename: A
authors.initials: A
authors.lastname: Bomzon
authors.forename: Y T
authors.initials: YT
authors.lastname: Huang
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism; D004195:Disease Models, Animal; D006975:Hypertension, Portal / Q000503:physiopathology*; D066298:In Vitro Techniques; D008099:Liver / Q000098:blood supply / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000503:physiopathology*; D008956:Models, Chemical; D024510:Muscle Development; D009131:Muscle, Smooth, Vascular / Q000254:growth & development / Q000502:physiology*; D010716:Phosphatidylinositols / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000819:agonists / Q000737:chemistry / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D013152:Splanchnic Circulation / Q000502:physiology; D014661:Vasoconstriction / Q000502:physiology
chemical_list: D010716:Phosphatidylinositols; D011956:Receptors, Cell Surface; D000242:Cyclic AMP; D011494:Protein Kinases; D006152:Cyclic GMP